Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
26
AVXL Quote, Financials, Valuation and Earnings
Last price:
$4.45
Seasonality move
:
3.46%
Day range:
$4.29 - $4.58
52-week range:
$2.86 - $14.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.19x
Volume:
1.9M
Avg. volume:
3.5M
1-year change:
-50.88%
Market cap:
$397.6M
Revenue:
--
EPS (TTM):
-$0.54
Analysts' Opinion
-
Consensus RatingAnavex Life Sciences Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.00, Anavex Life Sciences Corp. has an estimated upside of 394.38% from its current price of $4.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $4.45.
Fair Value
-
According to the consensus of 3 analysts, Anavex Life Sciences Corp. has 394.38% upside to fair value with a price target of $22.00 per share.
AVXL vs. S&P 500
-
Over the past 5 trading days, Anavex Life Sciences Corp. has overperformed the S&P 500 by 15.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Anavex Life Sciences Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Anavex Life Sciences Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Anavex Life Sciences Corp. reported revenues of --.
Earnings Growth
-
Anavex Life Sciences Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Anavex Life Sciences Corp. reported earnings per share of -$0.11.
Enterprise value:
295M
EV / Invested capital:
3.11x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-1.43x
EV / Free cash flow:
-7.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-39.77%
Net Income Margin (TTM):
--
Return On Equity:
-44.87%
Return On Invested Capital:
-44.87%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$55.8M | -$52.9M | -$51.4M | -$14.3M | -$10.8M | |
| EBITDA | -$55.8M | -$52.9M | -$51.4M | -$14.3M | -$10.8M | |
| Diluted EPS | -$0.60 | -$0.51 | -$0.54 | -$0.14 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M | |
| Total Assets | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M | |
| Current Liabilities | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M | |
| Total Liabilities | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M | |
| Total Equity | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.8M | -$30.8M | -$39M | -$6.7M | -$8.6M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $29.7M | $12M | $9.4M | $89K | $10M | |
| Free Cash Flow | -$27.8M | -$30.8M | -$39M | -$6.7M | -$8.6M | |
AVXL
Sector
Market Cap
$397.6M
$28.4M
Price % of 52-Week High
30.82%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-1.57%
-1.32%
1-Year Price Total Return
-50.88%
-22.19%
Beta (5-Year)
1.155
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.84
200-day SMA
Sell
Level
$8.74
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.61
Relative Strength Index (RSI14)
Sell
Level
40.44
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-19.697
50-day SMA
Sell
Level
$7.12
MACD (12, 26)
Sell
Level
-0.96
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (46.0387)
Sell
CA Score
(Annual)
Level (-0.5716)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (8.283)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, AVXL has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AVXL average analyst price target in the past 3 months is $22.00.
-
Where Will Anavex Life Sciences Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Anavex Life Sciences Corp. share price will rise to $22.00 per share over the next 12 months.
-
What Do Analysts Say About Anavex Life Sciences Corp.?
Analysts are divided on their view about Anavex Life Sciences Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Anavex Life Sciences Corp. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Anavex Life Sciences Corp.'s Price Target?
The price target for Anavex Life Sciences Corp. over the next 1-year time period is forecast to be $22.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AVXL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Anavex Life Sciences Corp. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVXL?
You can purchase shares of Anavex Life Sciences Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Anavex Life Sciences Corp. shares.
-
What Is The Anavex Life Sciences Corp. Share Price Today?
Anavex Life Sciences Corp. was last trading at $4.45 per share. This represents the most recent stock quote for Anavex Life Sciences Corp.. Yesterday, Anavex Life Sciences Corp. closed at $4.45 per share.
-
How To Buy Anavex Life Sciences Corp. Stock Online?
In order to purchase Anavex Life Sciences Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AVXL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AVXL
Sector
P/E ratio
--
23.66x
PEG ratio
-1.43x
-0.01x
P/B ratio
4.19x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
AVXL
Sector
Revenue growth
--
4.85%
Earnings growth
16.5%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.15
-$0.20
Profitability
AVXL
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
-44.87%
-30.98%
Return on assets
-39.77%
-27.62%
Return on equity
-44.87%
-36.69%
Earnings Date
Last Earnings Date
Nov
25
Next Earnings Date
Feb
9
Estimated Next Earnings Date
Feb
24
Balance Sheet
AVXL
Sector
Total cash
$102.6M
$27.2M
Short term investments
--
$25.7M
Total assets
$103.8M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
